Arcutis Biotherapeutics, Inc.

ARQTNASDAQHealthcareBiotechnology

$28.84- (-)1Y +39.37%

As of Oct 16, 2026 close

Market cap: $3.95B
P/E (TTM): 138.67
Forward P/E: -
Dividend yield: -
52-week range: $19.30$31.77
Volume (live): -
Avg. volume (3M): 3.09M

Arcutis Biotherapeutics, Inc. (ARQT) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Arcutis Biotherapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 9 professional research analysts

Consensus Rating

Buy

Based on 9 unique analysts

(12 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$37.00

+28.29% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest ARQT Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 6, 2026	Bret Jensen	TheStreet.com	Initiates Coverage	Buy	-
Sep 21, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Buy	-
Aug 27, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Buy	-
Aug 26, 2026	Ekta Bagri	Zacks Equity Research	Initiates Coverage	Buy	-
Aug 11, 2026	Douglas Tsao	HC Wainwright	Reiterates	Buy	$34.00
Aug 6, 2026	Seamus Fernandez	Guggenheim	Reiterates	Buy	$35.00 → $38.00 +3.00 (+8.6%)
Aug 6, 2026	Tyler Van Buren	TD Cowen	Maintains	Buy	$35.00
Aug 6, 2026	Serge Belanger	Needham	Reiterates	Buy	$40.00
Aug 6, 2026	Judah Frommer	Morgan Stanley	Reiterates	Buy	$34.00 → $38.00 +4.00 (+11.8%)
Aug 5, 2026	Seamus Fernandez	Guggenheim	Initiates Coverage	Buy	$35.00 → $38.00 +3.00 (+8.6%)
Aug 5, 2026	Tyler Van Buren	TD Cowen	Maintains	Buy	$35.00
Jul 23, 2026	Edmund Ingham	Forbes	Initiates Coverage	Hold	-

Bret Jensen

TheStreet.com

BuyInitiates Coverage

Oct 6

Zacks Equity Research

BuyInitiates Coverage

Sep 21

Zacks Equity Research

BuyInitiates Coverage

Aug 27

Ekta Bagri

Zacks Equity Research

BuyInitiates Coverage

Aug 26

Douglas Tsao

HC Wainwright

BuyReiterates

$34.00

Aug 11

Seamus Fernandez

Guggenheim

BuyReiterates

$35.00 → $38.00

Aug 6

Tyler Van Buren

TD Cowen

BuyMaintains

$35.00

Aug 6

Serge Belanger

Needham

BuyReiterates

$40.00

Aug 6

Judah Frommer

Morgan Stanley

BuyReiterates

$34.00 → $38.00

Aug 6

Seamus Fernandez

Guggenheim

BuyInitiates Coverage

$35.00 → $38.00

Aug 5

Tyler Van Buren

TD Cowen

BuyMaintains

$35.00

Aug 5

Edmund Ingham

Forbes

HoldInitiates Coverage

Jul 23

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 6, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for ARQT?

The analyst consensus rating for ARQT is Buy, based on the latest ratings from 9 analysts over the last 90 days.

What is the average price target for ARQT?

The average 12-month price target for ARQT is $37.00, representing an upside of 28.3% from the Oct 16, 2026 close of $28.84.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.